What is the current size and annual growth rate of the tenofovir disoproxil market?
The tenofovir disoproxil market size has grown strongly in recent years. It will grow from $3.58 billion in 2024 to $3.79 billion in 2025 at a compound annual growth rate (CAGR) of 5.9%. The growth in the historic period can be attributed to the growth in awareness and early detection of viral infections, rising cases of hepatitis b infections, expansion of generic drug manufacturing for tenofovir disoproxil, rising number of clinical trials supporting tenofovir efficacy, and growth in healthcare funding for infectious disease treatment.
The tenofovir disoproxil market size is expected to see strong growth in the next few years. It will grow to $4.72 billion in 2029 at a compound annual growth rate (CAGR) of 5.6%. The growth in the forecast period can be attributed to the rising demand for long-acting tenofovir formulations, increasing focus on combination therapies with newer antivirals, rising regulatory approvals for novel tenofovir combinations, rising focus on pediatric formulations of tenofovir, and increasing demand for tenofovir in post-exposure prophylaxis. Major trends in the forecast period include development of novel drug delivery systems, integration of artificial intelligence in drug development, advancements in combination therapies, advancements in nanotechnology-based delivery, and advancements in fixed-dose combination therapies.
Get Your Free Sample of The Global Tenofovir Disoproxil Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21296&type=smp
Which major factors have contributed to the expansion of the tenofovir disoproxil market?
The increasing prevalence of HIV and AIDS is expected to propel the growth of the tenofovir disoproxil market going forward. HIV and AIDS is a chronic viral infection that weakens the immune system by attacking CD4 cells, making the body vulnerable to infections and diseases. The increasing prevalence of HIV and AIDS is driven by factors such as unprotected sexual contact, lack of awareness, limited access to healthcare, and drug-resistant virus strains. The rising prevalence of HIV and AIDS is driving higher demand for tenofovir disoproxil, as it is a key antiretroviral drug used for treatment and prevention. For instance, in July 2024, according to a report published by the Joint United Nations Programme on HIV/AIDS (UNAIDS), a Switzerland-based government organization, by the end of 2022, approximately 39.5 million people were living with HIV worldwide, with about 1.3 million new infections reported that year. In 2022, around 630,000 deaths from AIDS-related illnesses occurred globally. Furthermore, 39.9 million (36.1 million–44.6 million) people globally were living with HIV in 2023. Therefore, the increasing prevalence of HIV and AIDS is driving the growth of the tenofovir disoproxil market.
Rising Hepatitis B Cases Fuel Demand For Antiviral Treatment
The growing prevalence of hepatitis B is expected to fuel the growth of the tenofovir disoproxil market going forward. Hepatitis B is a viral infection that attacks the liver, potentially causing both acute and chronic disease, and is transmitted through contact with infected blood or bodily fluids. The growing prevalence of hepatitis B is driven by factors such as perinatal transmission, unsafe medical practices, lack of vaccination coverage, and the persistence of chronic infections in affected populations. Tenofovir disoproxil is used in the treatment of chronic hepatitis B to suppress viral replication and reduce liver damage. For instance, in March 2023, according to a report published by the Centers for Disease Control and Prevention, a US-based government agency for protecting public health, in the United States, an estimated 580,000 to 2.4 million people are living with hepatitis B infection, with about two-thirds potentially unaware of their condition. Therefore, the growing prevalence of hepatitis B is driving the growth of the tenofovir disoproxil market.
How is the tenofovir disoproxil market segmented?
The tenofovir disoproxil market covered in this report is segmented –
1) By Type: Tablet, Powder
2) By Distribution Channel: Online Pharmacies, Retail Pharmacies, Wholesalers Or Distributors
3) By Application: Hospital, Clinic
Subsegments:
1) By Tablet: Single-Drug Tablets, Fixed-Dose Combination Tablets
2) By Powder: Oral Powder, Reconstitutable Powder
Order your report now for swift delivery
https://www.thebusinessresearchcompany.com/report/tenofovir-disoproxil-global-market-report
Who are the top competitors in the tenofovir disoproxil market?
Major companies operating in the tenofovir disoproxil market are Gilead Sciences Inc., Viatris Inc., Teva Pharmaceuticals Limited, Cipla Ltd, Lupin Limited, Mylan NV, Blanver, SMS Pharmaceuticals, Bajaj Healthcare, Mangalam Drugs & Organics Ltd, Nortec Quimica, Arene Lifesciences, Cdymax, HRV Global Life Sciences, Pipelinepharma, Qilu Pharmaceutical, Jai Radhe Sales, Sinoway Industrial Co. Ltd, Aurisco Pharmaceutical, Huangshi Fuertai Pharmaceutical Tech Co. Ltd
Which key trends are expected to influence the tenofovir disoproxil market in the coming years?
Major companies operating in the tenofovir disoproxil market are focusing on the development of new formulations, such as combination therapy, to gain a competitive edge and enhance treatment of HIV/AIDS disease. Combination therapy refers to the simultaneous use of two or more treatments, often medications, to enhance therapeutic effects and improve patient outcomes for a specific condition. For instance, in July 2022, Gilead Sciences Inc., a US-based biopharmaceutical company, announced the approval of Vemlidy (tenofovir alafenamide) by the U.S. Food and Drug Administration (FDA) for the treatment of chronic hepatitis B virus (HBV) infection in pediatric patients aged six years and older who weigh at least 25 kg and have compensated liver disease. The FDA’s approval of Vemlidy for this younger age group was based on data from a Phase II clinical trial that showed the drug’s safety and efficacy in children as young as six years old.
Which regional trends are influencing the tenofovir disoproxil market, and which area dominates the industry?
North America was the largest region in the tenofovir disoproxil market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the tenofovir disoproxil market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
What Does The Tenofovir Disoproxil Market Report 2025 Offer?
The tenofovir disoproxil market research report from The Business Research Company offers global market size, growth rate, regional shares, competitor analysis, detailed segments, trends, and opportunities.
Tenofovir disoproxil is a medication used to treat HIV-1 infection and chronic hepatitis B. As a prodrug of tenofovir, it transforms into its active form in the body, preventing viruses from replicating. It falls under the nucleotide reverse transcriptase inhibitors (NRTIs) class, which block a key enzyme necessary for viral multiplication.
Purchase the exclusive report now to unlock valuable market insights:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21296
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
